Healthcare
Allergy Therapeutics plc(AGYTF)
Live Price
Offline$0.13
+0.00% today
1Y Change
+52.94%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $510.00M
- Revenue Growth
- +36.9%
- EPS Growth
- +21.5%
- Dividend Yield
- 0.0%
Coverage: 257 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Allergy Therapeutics plc (AGYTF) is a Healthcare stock with a market cap of $510.00M and listed on OTC. The stock last traded around $0.13 and up 52.9% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +36.9%, EPS growth of +21.5%, a dividend yield of 0.0%. What stands out right now is revenue +36.9%, EPS +21.5%, free cash flow -23.5% with operating margin -60.2% and ROIC -84.3%. Valuation already assumes a fairly strong business story at price/sales 9.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines AGYTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+36.9% vs +7.6% peer median
Operating Margin
Below sector median
-60.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 31, 2026 with revenue below estimates by -0.1%.
The operating story is still moving forward
Revenue is running at +36.9% and EPS at +21.5%, with operating margin around -60.2%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 30, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 31, 2026 | +0.0% | +0.0% | +0.0% | +0.0% |
2025 Dec 11, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Mar 31, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Edge
AGYTF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
AGYTF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
AGYTF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for AGYTF and SPY.
Company Overview
Allergy Therapeutics plc
Other OTC
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
- Leadership
- Manuel Llobet
- IPO Date
- Feb 3, 2010
- Employees
- 612
- Street Address
- Dominion Way
- Mailing
- Worthing, BN14 8SA
- Region
- Worthing, GB
- Reporting Currency
- USD
- Investor Line
- 44 1903 844 700
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 9.0
- Price/Book
- 125.4
Growth
- Revenue
- +36.9%
- EPS
- +21.5%
- Free Cash Flow
- -23.5%
Profitability
- Gross Margin
- 41.2%
- Operating Margin
- -60.2%
- Net Margin
- -85.5%
- ROE
- 409.0%
- ROIC
- -84.3%
Balance Sheet
- Debt/Equity
- 6.30
- Current Ratio
- 1.13
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.